DLL-3 is an inhibitory Notch pathway ligand that mediates oncogenesis in melanoma, bladder, endometrial, ovarian, pancreatic, and lung cancer via multiple mechanisms, including angiogenesis, tumour stromal remodelling, and effects on immune cells in the tumour stroma [123]. Here, DLL3 is linked to neoplasm.